SynthesisFrontiers in medicine2026
Serum M2BPGi as a predictor of hepatocellular carcinoma development in chronic hepatitis B and C: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) kills about 830,000 people each year, and most cases arise in chronic viral hepatitis. Better risk markers would let clinicians focus surveillance where it matters. Mac-2 binding protein glycosylation isomer (M2BPGi) is a serum glycobiomarker of liver fibrosis. Several cohort studies tie elevated M2BPGi to HCC. No quantitative synthesis has pooled this evidence across viral etiologies. Methods: We searched PubMed/MEDLINE, Embase, the Cochrane Library, Web of Science, and Scopus through April 2026 for longitudinal studies that reported hazard ratios (HRs) for HCC linked to elevated M2BPGi in chronic hepatitis B (CHB) or C (HCV). We registered the protocol with PROSPERO. The primary pool restricted to longitudinal studies with categorical cutoffs that reported HRs. We used random-effects meta-analysis with restricted maximum likelihood and the Hartung-Knapp adjustment. Results: Twenty-three publications (24 study entries) met inclusion criteria. The primary pool of 15 longitudinal categorical HR-reporting studies covered 12,161 participants and at least 1,189 HCC events. The pooled HR was 4.61 (95% CI 3.24-6.54; Conclusion: Elevated serum M2BPGi is strongly and consistently associated with HCC development in patients with chronic hepatitis B and C. The effect holds across etiology, treatment status, and measurement timing-including after sustained virological response. Funnel asymmetry suggests the true effect is closer to a 3.5-fold than a 4.6-fold risk increase, still large enough to matter clinically. M2BPGi is a credible candidate to layer onto current viral hepatitis surveillance, particularly for risk stratification after virological control. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261372566, identifier CRD420261372566.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.